“The LN P3 trial did not have a DMC in the scope. (caution)...what I did was a cursory look so take this information with a grain of salt but it looked to me like neither the FDA or AUPH is planning on anybody getting a mid-point look in.”
I expect the data will not be all that convincing half way through as it will be at the end of the trial. Remember the efficacy in the P2b trial was much better at 48 weeks than it was 24 weeks. Having a look see half way through and the data is weak would cause your stock to plunge (as if we need any more of that!).
News 
Market Data 
Discover 
